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Bronchial asthma often remains uncontrolled despite treatment with inhaled corticosteroids
(ICS), long-acting b2-agonists (LABA) or both, necessitating additional treatment. Patients
18 years (nZ 1681) with mild-to-moderate asthma received oral montelukast 10 mg added
to ICS or ICS þ LABAs, and were followed for 6 months in a prospective, open-label observa-
tional study. The primary endpoint was change in Asthma Control Test (ACT) score. Secondary
endpoints included mini-Asthma Quality-of-Life Questionnaire (mini-AQLQ) and FEV1/PEF.
Mean ACT scores improved from 14.6  4.6 (baseline) to 19.4  4.4 (month 6; p < 0.0001).
Using ACT score categories, the percentage of patients with uncontrolled (57.5%) or poorly
controlled (25.0%) asthma at baseline decreased at month 6 (17.6 and 21.7%, respectively);
the percentage of patients with well controlled (13.9%) or completely controlled (1.2%) asthma
at baseline increased at month 6 (47.5 and 11.4%, respectively). The mini-AQLQ score
(mean  SD) improved from 4.0  1.1 to 5.3  1.1 (p < 0.0001); FEV1 increased from
2.46  0.89 to 2.60  0.92 L (p < 0.0001). Treatment with montelukast was generally well
tolerated. In patients insufficiently controlled with ICS or ICS þ LABAs, daily add-on montelu-
kast improved both asthma control and asthma-related quality of life. Clinicaltrials.gov
registry number NCT00802789.
ª 2009 Elsevier Ltd. All rights reserved.tsklinikum Rostock, Medizinische Klinik und Poliklinik, Abteilung fu¨r Pneumologie, Ernst-Heydemann-
el.: þ49 381 494 7460; fax: þ49 381 494 7392.
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Asthma affects 300 million people worldwide and is asso-
ciated with considerable morbidity and, at times,
mortality.1,2 Current hypotheses suggest that inflammation
is the underlying cause of symptoms, which include
wheeze, breathlessness, chest tightness, and coughing.3e5
The cellular bronchial infiltrations in asthma are associated
with elevated levels of inflammatory mediators such as
leukotrienes.
Current guidelines for asthma management concur that
inhaled corticosteroids (ICS) are the mainstay of anti-
inflammatory therapy in asthma.1,6,7 Nevertheless, asthma
is often inadequately controlled, even with high doses of
ICS, warranting additional therapies. Accordingly, long-
acting b2 agonists (LABAs) are commonly used in combina-
tion with ICS.1 While the addition of LABAs to ICS results in
an improvement in symptom scores and reduces exacer-
bations, recent studies have shown that insufficiently
controlled asthma remains a significant problem even when
ICS and LABAs are titrated to the maximal dose.8,9 There-
fore, alternative therapies that can be added either to ICS
or to ICS þ LABA are needed.
Cysteinyl leukotrienes (CysLT) mediate tissue edema,
infiltration and activation of inflammatory cells. Accord-
ingly, leukotriene modifiers have been shown in random-
ized, placebo controlled clinical trials to improve airflow
limitation and asthma symptoms.10e14 Additionally, add-
on therapy with leukotriene receptor antagonists (LTRAs)
to ICS or ICS e b2-agonist combinations have demon-
strated improved asthma control and pulmonary function
in similar, controlled trials.15e18 However, translating
randomized controlled clinical trial data to everyday
clinical practice is often difficult when treating patients
who might not fulfill the inclusion criteria of these
studies. To complement the results of these randomized
double-blind studies, increasing emphasis is put on the
added value of open-label studies under ‘‘real-world’’
conditions that provide clinically relevant additional
information about the actual benefits of these therapies
in broader patient populations. Dupont et al.19 reported
that adding montelukast to a fixed combination of ICS and
LABA improved asthma control and pulmonary function in
a 2-month open-label pilot study in 313 insufficiently
controlled asthma patients. Korn et al. found similar
results in a comparably designed study in 5769 patients
and provide further evidence of the efficacy of adding
montelukast to the treatment regimens of inadequately
controlled patients, although the study was also limited
in that the duration was only 2 months and that the
evaluation of treatment effects was limited to only one
time point.20 Because of the chronic nature of asthma
and the possibility of a better safety profile with long-
term LTRA therapy versus long-term LABA therapy,16
studies examining treatment over longer durations are
needed.
In this study, we report a substantially longer prospec-
tive open-label study in which montelukast was added to
treatment regimens of patients whose asthma, as judged by
their attending physician, was insufficiently controlled with
ICS or ICS þ LABA.Methods
Patients included in this study were 18 years of age with
a physicians’ diagnosis of mild or moderate persistent
asthma defined as Global Initiative for Asthma (GINA) stage
II or stage III, respectively1 who were insufficiently
controlled with their current medication of ICS or ICS and
LABAs. Uncontrolled asthma was defined according to GINA
criteria.1 No further restrictions were placed on qualifica-
tions for patient inclusion in order to emulate ‘‘real world’’
clinical practice. Patients were enrolled if they met the
criteria of uncontrolled asthma according to their physi-
cians’ assessment.
This study was conducted at 290 sites in Germany by
office-based pulmonary specialists. Each study site was to
include a maximum of five patients in order to limit inves-
tigator bias. Patients were informed about the study and
signed an informed consent prior to participation. The
study was registered with the German federal authorities
and the Ethics committee as per the German Medicines Act.
The study was also registered with clinicaltrials.gov
(NCT00802789) and within the registry of non-interven-
tional studies of the Association of Research Based Phar-
maceutical Companies.
This was a prospectively designed, open-label study
conducted between April 2007 and September 2008; the
duration was 6 months. At visit 1 (baseline visit), asthma
control was assessed with the five-question Asthma Control
Test (ACT) and asthma-related quality-of-life was assessed
using the mini-Asthma Quality-of-Life Questionnaire (mini-
AQLQ).21 In addition, pulmonary function (spirometry) was
measured in patients not well controlled. At the first visit,
patients received montelukast 10 mg for daily self-adminis-
tration, in addition to their current asthma treatment. These
concomitant medications included short-acting b2-agonists,
ICS, LABA, fixed combinations of ICS þ LABA, theophylline
or, in some patients, oral corticosteroids.
At visit 2 (month 3) and visit 3 (month 6), ACT and mini-
AQLQ evaluations were completed in the office, spirometry
was conducted if deemed necessary by the physician, and
satisfaction with therapy and adverse events (AEs) were
documented. Between visits (1.5 and 4.5 months), patients
filled out another ACT (at home) and gave self-assessments
of compliance (by pill count); for compliance assessments,
a four-stage scale was applied (zero to one tablet per week,
two to three tablets per week, four to five tablets per
week, six to seven tablets per week).
Efficacy analyses were performed for the intention to
treat (ITT) population and for the per-protocol (PP) pop-
ulation; safety was evaluated using the total set. The PP
population included patients fulfilling the following
criteria: age of patient 18 years; uncontrolled asthma
under previous therapy with either ICS or ICS þ LABA; and
at least one on-treatment efficacy value. The data pre-
sented in this report show results from the ITT.
The primary endpoint was the total score from the ACT,
which consists of five questions rated on a scale from 1 to 5
(Table 1). The results of individual questions were added up
to a total score, with a range between 5 (completely
uncontrolled asthma) and 25 (completely controlled
asthma). Patients were placed into the following four
Table 1 Individual questions of the ACT.
1 In the past 4 weeks, how much of the time did your asthma keep you from getting as much done at work,
school or at home as usual?
2 During the past 4 weeks, how often have you had shortness of breath?
3 During the past 4 weeks, how often did your asthma symptoms (wheezing, coughing, shortness of breath,
chest tightness or pain) wake you up at night or earlier than usual in the morning?
4 During the past 4 weeks, how often have you used your rescue inhaler or nebulizer medication (such as salbutamol)?
5 How would you rate your asthma control during the past 4 weeks?
*Score of 1Z worst asthma control for each question; score of 5Z best asthma control for each question. ACTZ asthma control test.
646 J.C. Virchow et al.different categories based on their results: (1) <16 (uncon-
trolled); (2) 16 to 19 (poorly controlled); (3) 20 to 24
(well controlled); and (4) 25 (completely controlled).
The German version of the validated mini-Asthma
Quality-of-Life Questionnaire (mini-AQLQ) by Juniper et al.
was used as a secondary endpoint.21 This patient-
completed questionnaire consists of 15 questions concern-
ing four domains (symptoms, impairment in activities,
emotional life, and environmental impulses). All questions
are rated on a scale from 1 to 7. Low values represent poor
quality of life; high values represent good quality of life.21
Forced expiratory volume in 1 s (FEV1; L) and peak expira-
tory flow (PEF; L/s) were documented by spirometry based
on individual physician’s decisions during the visits. Addi-
tionally, physicians’ and patients’ satisfaction with therapy
were recorded.
All AEs were documented in detail in special case report
forms, which were sent to the clinical research organization
(CRO; Kendle, Munich). Serious AEs (SAEs) were AEs that
resulted in death, hospitalization, birth defects, disability,
malignancy, or were life threatening as well as incidences
of overdose regardless of outcome; these were reported
immediately to the CRO.
Sample mean and standard deviation were reported for
continuous endpoints, and proportions were reported
for the categorical endpoints at baseline, months 3 and 6.
For changes in ACT, mini-AQLQ, and lung function param-
eters during the course of the study, 95% confidence
intervals and significance tests at the 5% level were
generated using the t-distribution. The tests are descriptive
and have no confirmatory character.
No adjustment of significance level was made due to
multiple testing. In order to validate the results in the
absence of distributional assumptions for a t-test, a non-
parametric test (i.e., sign test) was used for sensitivity. As
a non-parametric test, a sign test does not require any
specific distribution for the underlying values. The two
tests had a very similar outcome, and the results of the sign
test support those of the t-test. The number of patients
with AEs and discontinuations from this study were also
reported.Results
A total of 1681 patients participated in this study. Patient
demographics and symptoms are shown in Table 1. On
average, the duration of asthma was 11.5 years. Patients on
ICS alone constituted 23.1%, and those on ICS þ LABA (free
or fixed combination) were 69.5%. Despite these treatmentapproaches patients were determined by their physicians to
be insufficiently controlled (Table 1).
For the majority of patients, montelukast treatment was
continued after the study ended (86.8% were continued
after month 3 and 87.3% after month 6). The most common
reasons for specialists not to continue montelukast treat-
ment were: continued prescription of montelukast by the
family doctor, no improvement of the asthma status while
treated with montelukast, patient’s request to stop treat-
ment, patient still had enough tablets at home, and
discontinuation of treatment because asthma symptoms
were seasonal. In 37 of 282 patients who discontinued
treatment with montelukast, the asthma status improved
so that further treatment was no longer necessary.
At baseline, the mean ACT score for all patients (inten-
tion-to-treat analysis) included in the study was 14.6  4.6
and improved significantly at 3 (18.8  4.4; p < 0.0001) and
6 months (19.4  4.4; p < 0.0001) with add-on montelukast
treatment. Results for the per-protocol (PP) analysis were
consistent with that of the intention-to-treat (ITT) analysis:
the mean ACT score at baseline for the PP-analysis was
14.4  4.5 and improved significantly at 3 (18.7  4.4;
p < 0.0001) and 6 months (19.3  4.4; p < 0.0001). In
addition, patients’ responses to the ACTwere classified into
four categories; the proportion of patients in each of the
categories improved from baseline to month 6, reflecting
an improvement in asthma control (Figure 1).
At baseline, when patients were grouped into different
stages of control, more than half of all patients (57.5%) were
uncontrolled (ACT total score <16) and 25.0% were poorly
controlled (ACT total score 16 to 19); only 13.9% had well-
controlled asthma (ACT total score 20 to 24) and 1.2% of
patients had completely controlled asthma according to the
ACT (ACT total scoreZ 25). This distribution reflects that
physicians still considered a need for additional therapy
according to their clinical assessment even in some patients
with a high ACT score. After 6 months of open-label treat-
ment with montelukast, the percentage of patients with
completely controlled asthma increased from 1.2 to 11.4%
and those with well-controlled asthma increased from 13.9
to 47.5%. The percentage of patients with poorly controlled
asthma decreased from 25.0 to 21.7%, and those with
uncontrolled asthma decreased from 57.5 to 17.6%.
Figure 2 shows data for the individual questions of the
ACT. There was a marked improvement from baseline by
month 3 in mean scores for each question. These scores
improved further, although less markedly, from months 3
(visit 2) to 6 (visit 3) of add-on LTRA treatment (Figure 2).
The overall score of themini-AQLQ significantly improved
at 3 and 6 months (Table 2). Improvements were observed in
Figure 1 Percentage of patients with total ACT scores by
category; <16Z uncontrolled asthma, 16e19Z poorly cont-
rolled asthma, 20e24Z well controlled asthma, 25Z com-
pletely controlled. ACTZ asthma control test.
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(visits 1e3) were 3.9  1.2 to 5.2  1.2 (p < 0.0001) for the
‘‘symptoms’’ domain; 4.3  1.3 to 5.4  1.3 (p < 0.0001) for
the ‘‘impairment in activities’’ domain; 4.2  1.4 to
5.5  1.3 (p < 0.0001) for the ‘‘emotional life’’ domain, andFigure 2 Responses to individual questions of the Asthma Contr
responses from some patients in the study. BLZ baseline; Mo 3Z
following with responses from 1 (worst) to 5 (best): Question 1: In th
from getting as much done at work, school, or at home? Question 2
breath? Question 3: During the past 4 weeks, how often did your ast
tightness or pain) wake you up at night or earlier than usual in the
you used your rescue inhaler or nebulizer medication? Question 5: H3.8  1.3 to 4.8  1.4 (p < 0.0001) for the ‘‘environmental
impulses’’ domain (Table 3).
Total values for pulmonary function improved from an
FEV1 of 2.46  0.89 L at baseline to 2.60  0.92 L at
6 months (p < 0.0001), whereas the PEF increased from
5.76  2.38 to 6.22  2.47 L/s (p < 0.0001) (Table 2).
Additionally, examination of the % of predicted normal
value for FEV1 and PEF show that, although spirometry was
only conducted in patients who were deemed as not well
controlled, the percent of patients experiencing subop-
timal lung function dropped from the baseline visit to
months 3 and 6 (Figure 3; Table 3).
After 6 months of treatment, 83.2% of physicians and
83.4% of patients rated the overall improvement in asthma
as either ‘‘better’’ or ‘‘very much better’’ compared with
baseline. Only 15.0% of patients and 15.3% of physicians
reported ‘‘no improvement.’’
Non-serious AEs were reported by 76 patients (4.5% of all
patients). The most frequently reported AEs as grouped by
system-organ class were infections and infestations
(26 patients, 1.6%), gastrointestinal disorders (17 patients,
1.0%) and skin and subcutaneous disorders (14 patients,
0.8%). The following were the most common individual AEs:
infection (11 patients), headache (seven patients), nausea,
and asthma (in each case six patients), nasopharyngitis and
sleep disorder (in each case five patients). Psychiatric AEs
were not commonly reported as a system-organ class.
There were 11 patients reporting psychiatric AEs: three
reported anxiety, one reported hallucination, one reportedol Test (ACT). Bars do not add up to 100% because of missing
month 3; Mo 6Z month 6. Individual questions included the
e past 4 weeks, how much of the time did your asthma keep you
: During the past 4 weeks, how often have you had shortness of
hma symptoms (wheezing, coughing, shortness of breath, chest
morning? Question 4: During the past 4 weeks, how often have
ow would you rate your asthma control during the past 4 weeks?
Table 2 Patient demographics.
n Value
Total patients included in study 1681 N/A
Age, yr, mean  SD 1665* 45.7  15.9
Gender, %
Male 567 33.7
Female 1097 65.3
Presence of allergic rhinitis 986 58.7
Proportion of patients, %
Lung function (PEF or FEV1)
<80% of predicted value
610 36.3
Asthma severity: mild asthma 572 34.0
Asthma severity:
moderate asthma
1036 61.6
Daytime symptoms
>2/week
1213 72.2
Any constraint of physical
activities
614 36.5
Any nocturnal asthma
symptoms/nocturnal
awakening
621 36.9
Rescue medication use >2/week 964 57.3
Exacerbations 1/year 752 44.7
Asthma not controlled
despite ICS or ICS þ LABA
1590** 94.6
*There were 16 patients whose age was not documented. **All
patients included in this study were inadequately controlled
according to GINA guidelines; however, data on GINA criteria
determining uncontrolled asthma is missing from 91 patients;
FEV1Z forced expiratory volume in 1 s; ICSZ inhaled cortico-
steroid; LABAZ long acting b2 agonist; PEFZ peak expiratory
flow; SDZ standard deviation.
Table 3 Secondary endpoint assessments.
Visit n* Mean value
 SD**
FEV1 (L) 1 1445 2.46  0.89
2 1057 2.61  0.92
3 914 2.60  0.92
FEV1 (% of predicted value) 1 1441 79.2  21.2
2 1050 84.0  22.2
3 908 84.3  21.9
PEF (L/s) 1 967 5.76  2.38
2 669 6.20  2.33
3 563 6.22  2.47
PEF (% of predicted value) 1 967 78.1  29.5
2 663 84.7  29.1
3 557 85.3  31.6
Mini-AQLQ overall score 1 1605 4.0  1.1
2 1409 5.0  1.1
3 1261 5.3  1.1
*Not all patients were included in secondary endpoints. The
performance of these tests were made at the discretion of
individual investigators; **P < 0.0001 for differences between
visit 1 and visits 2 and 3 for all assessments; AQLQZ asthma
quality-of-life questionnaire; PEFZ peak expiratory flow;
FEV1Z forced expiratory volume in 1 s; SDZ standard
deviation.
Figure 3 FEV1 and PEF (% of predicted normal value). FEV1 and
PEF measurements were not performed for patients with well-
controlled asthma; therefore, an increase in the percentage of
patients with 80% FEV1 or PEF would not be expected in this
figure. Totals <100% due to missing values for those patients
whose lung function was not measured due to well controlled
asthma; nZ total number of patients. FEV1Z forced expiratory
volume in 1 s; PEFZ peak expiratory flow.
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ness, and five reported sleep disorder.
SAEs were reported by six patients (0.4% of all patients),
none of which were considered related to montelukast.
SAEs included one gastric cancer, one septic shock
(with lethal outcome), one urinary bladder cancer, one
meniscus damage, one asthma exacerbation, one asthma
exacerbation due to an infection, and one acute bronchitis.
Discussion
In this large, real-life, multi-center study conducted by
pulmonary specialists in private practice the addition of
a leukotriene receptor antagonist to patients who were
considered to be insufficiently controlled on ICS or ICS and
LABAs resulted in a significant and clinically relevant
improvement in asthma control as assessed by the ACT and
in asthma related quality of life as assessed by the mini-
AQLQ. While the recommended strategy for uncontrolled
asthma patients on ICS is to add a LABA,1 randomized,
controlled trials have suggested that asthma exacerbations
can also be reduced in patients receiving ICS by adding
a LTRA such as montelukast.22 Notably, in a randomized
controlled study, the number of asthma attacks and
nocturnal awakenings were similar in treatment regimens
using ICS þ LABA or ICS þ LTRA.15 Similarly, pulmonary
function improvement was not different when the addition
of an LTRA to a standard dose of ICS was compared with
doubling the dose of steroids.17
Additionally, it is well recognized that not all patients
achieve well-controlled asthma despite an appropriately
high dose of ICS or ICS þ LABA combination therapy;8 in
such patients, there is a need for additional add-on therapy
such as treatment with a LTRA. In a 6-week study in
symptomatic patients on high-dose ICS (1200 mg of BDP)
Add-on montelukast in inadequately controlled asthma patients 649and short-acting b2-agonists, the addition of an LTRA
(zafirlukast) significantly improved lung function and
reduced exacerbations.18 In addition, in a smaller, open-
label study of 313 patients with insufficiently controlled
patients on fixed combination therapy with ICS and LABAs,
Dupont et al. observed an improvement in asthma symp-
toms and pulmonary function with add-on LTRA therapy
after 2 months of therapy.19
In this open-label study, add-on montelukast therapy in
a real-world setting over 3 and 6 months improved asthma
control in patients with mild to moderate persistent asthma
who were not sufficiently controlled by ICS or the combi-
nation of ICS and LABA. Asthma control was assessed by the
ACT, a short and relatively simple, validated, patient-
based, five-item questionnaire that is one of the assess-
ment tools for asthma control recommended by GINA.1,23,24
The total ACT scores and responses to individual questions
of the ACT in this study demonstrated improved asthma
control with the addition of montelukast. Interestingly,
results for the per-protocol population were consistent with
those seen for the total population (ITT-analysis) which
strongly suggests that the improvements observed are not
due to a selective drop out of patients who did not posi-
tively respond to therapy.
Previous studies in asthma have shown that the assess-
ment of asthma symptoms and severity can differ consid-
erably between physicians and patients.25 Interestingly,
when asked about their overall impression about the
effects of add-on montelukast in this study, the assessment
of the respective individual improvement was almost
identical when physicians’ and patients’ assessments were
compared. Thus, these results support the use of the ACT as
a primary outcome parameter in which patients and
physicians effectively communicate their observations on
asthma control on a common platform.
Additionally, add-on montelukast treatment was evalu-
ated by the validated German version of the mini-AQLQ,
the short form of the Asthma Quality-of-Life Question-
naire.21 The total mini-AQLQ score as well as its individual
questions also demonstrated a clinically meaningful
improvement when montelukast was added to current
therapy. Improvements in all of the domains of the test
were >0.5 points, which has been reported as the minimal
important difference (MID) of clinical relevance.21
In this study, SAEs were rare and were deemed to be
unrelated to montelukast. Psychiatric AEs were also rare;
the most common among this category of AEs was sleep
disorder, which was reported by five patients.
Thus, the results from this study confirm previous
randomized, well-controlled studies in smaller patient
populations with more rigid inclusion and exclusion criteria.
There are, however, limitations to this study, due to the
inherent biases introduced by an open-label design. In
a controlled environment with a smaller number of patients,
data such as the number of hospitalizations during the study,
the rate of exacerbations, and actual doses of ICS and LABA
medication taken by patients would be captured. Due to the
non-interventional design of this open-label study, such data
was not possible to capture. Another limitation to this open-
label design was that a small number of patients were
included in this study who were not uncontrolled according
to a strict interpretation of the GINA guidelines. However, itshould be noted that this study reflects results observed in
a real-world setting; outside the setting of a randomized
controlled trial, physicians continue to see patients who are
unsatisfied with their asthma therapy despite being defined
as well controlled by GINA criteria. Obviously, our study was
not designed to test the sensitivity and specificity of the
GINA criteria for ‘‘controlled asthma’’. The study reflects
the clinical experience that some patients despite fulfilling
the criteria of ‘‘controlled’’ asthma according to GINA will
seek further treatment options. However, the number of
such patients was very small and therefore does not affect or
confound the interpretation of results of this trial where the
vast majority of patients were uncontrolled as defined by
GINA criteria. Another limitation that should bementioned is
that this study was conducted exclusively in patients who
were treated in Germany; therefore similar studies in other
countries are needed to confirm that these results could be
replicated in other populations internationally.
Nevertheless, observational studies, particularly large
ones such as the present study, provide useful and important
additional and/or complementary information to random-
ized controlled trials and offer a view of treatment effects in
a ‘‘real-world’’ setting. In fact, the Brussels Declaration on
Asthma recently urged the funding of ‘‘real-world’’ studies
such as the present one and supported that the results of
such studies be used to inform treatment guidelines.26
In summary, the results from this large, open-label study
under ‘‘real-life’’ conditions demonstrate clinically relevant
improvements in patients with asthma when montelukast is
added to current ICS or ICS þ LABA therapy. These
improvements included asthma control, quality of life, lung
function, and asthma status with a good safety profile.
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